A Phase 1, Single-Centre, Open-Label, Two-Part, Sequential Cross-Over Study Designed to Assess the Pharmacokinetic Profile of BLU-5937 Following Administration of Extended Release Formulation Prototypes and an Immediate Release Reference Formulation in Healthy Male and Female Subjects
Latest Information Update: 27 May 2025
At a glance
- Drugs Camlipixant (Primary)
- Indications Cough
- Focus Pharmacokinetics
- Sponsors BELLUS Health
Most Recent Events
- 16 Jul 2024 Status changed from recruiting to completed.
- 22 Mar 2024 Planned End Date changed from 31 May 2024 to 28 Jun 2024.
- 22 Mar 2024 Planned primary completion date changed from 31 May 2024 to 28 Jun 2024.